EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE The company increased its 2024 revenue guidance to $620 – $650 million. Clinical Development "The results of the open-label phase of our GRACE trial, which we released last week, are compelling," said Dr. Belanoff. "We expect to build on these results in the trial's randomized withdrawal phase. Results from this portion of the study will be available in the coming weeks. We are on track to submit our ND ...

Corcept Therapeutics Incorporated (CORT) announced positive data from one part of the pivotal phase III GRACE study, which evaluated its lead pipeline candidate, relacorilant, for treating patients with all etiologies of endogenous Cushing’s syndrome.The GRACE study consists of two parts. The above mentioned data was from the open-label portion of the study in which patients with Cushing’s syndrome and either hypertension, hyperglycemia or both were treated with relacorilant for a period of 22 weeks.Data fr ...

MENLO PARK, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol, today announced positive results from the open-label portion of the pivotal Phase 3 GRACE trial of its proprietary selective cortisol modulator relacorilant in patients with all etiologies of end ...

Corcept Therapeutics (CORT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the sy ...

Corcept Therapeutics Incorporated (CORT) announced that it has completed enrollment in the phase II DAZALS study, which is evaluating its selective cortisol modulator, dazucorilant, for treating patients with amyotrophic lateral sclerosis (ALS), a degenerative neurologic disorder.The primary endpoint of this double-blind, placebo-controlled phase II study is to see the change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R), a measure of motor impairment and functional deterioration in AL ...

Corcept Therapeutics Incorporated (CORT) announced that it has completed enrollment in the phase III ROSELLA study, which is evaluating its lead pipeline candidate, relacorilant, in combination with Abraxane (nab-paclitaxel) for treating patients with recurrent, platinum-resistant ovarian cancer.The primary endpoint of this pivotal phase III study is progression-free survival, while overall survival is a key secondary endpoint. Progression-free survival data from the ROSELLA study is expected by 2024-end.Pr ...

MENLO PARK, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in ROSELLA, a pivotal Phase 3 trial of its proprietary selective cortisol modulator relacorilant combined with nab-paclitaxel in patients with recurrent, p ...

Corcept Therapeutics Incorporated (CORT) reported fourth-quarter 2023 earnings of 28 cents per share, which beat the Zacks Consensus Estimate of 25 cents. The company reported earnings of 14 cents per share in the year-ago quarter.Revenues increased 31% year over year to $135.4 million. The figure beat the Zacks Consensus Estimate of $130 million. The top line solely comprises product sales of Cushing’s syndrome drug, Korlym.Quarter in DetailRevenues from Korlym met our model estimate of $135.4 million.Rese ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2023 Earnings Conference Call February 15, 2024 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer, President and Director Sean Maduck - President, Corcept Endocrinology William Guyer - Chief Development Officer Conference Call Participants Matt Kaplan - Ladenburg Thalmann David Amsellem - Piper Sandler Swayampakula Ramakanth - H.C. Wainwright Joon Lee - Tru ...

MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2023. Financial Results Fourth quarter revenue of $135.4 million, a 31 percent increase over the same period in 2022Full year ...